VA
RYTM icon

VR Adviser’s Rhythm Pharmaceuticals RYTM Stock Holding History

VR Adviser’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-495,983
Closed -$22.8M – 41
2023
Q4 		$22.8M Sell
495,983
-594,017
-54% -$18.7M 1.56% 21
2023
Q3 		$25M Hold
1,090,000
– – 2.63% 15
2023
Q2 		$18M Buy
+1,090,000
New +$19.7M 2.87% 15

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser's RYTM Position: Q1 2024 in Review

VR Adviser sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2024, closing a stake of 495,983 shares — an estimated $22.8M sold.

VR Adviser first reported a position in RYTM in Q2 2023 and held it in 3 quarters. The position peaked at $25M in Q3 2023. 167 funds tracked by Wall St. Rank hold RYTM as of Q1 2024.

  • VR Adviser reported no remaining Rhythm Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • VR Adviser sold 495,983 Rhythm Pharmaceuticals shares in Q1 2024, an estimated $22.8M.
  • VR Adviser first reported a position in Rhythm Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • VR Adviser's Rhythm Pharmaceuticals position peaked at $25M in Q3 2023.
  • 167 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2024.

Based on VR Adviser's 13F filing for Q1 2024, filed 15 May 2024.